BLISS GVS PHARMA LTD. ca.s.s

May ll, 2021

To The Manager, Listing Department National Stock Exchange of India Ltd. Plot no. C/1 G Block , Bandra-Kurla Complex, Bandra (East), Mumbai- 400 051 Symbol: BLISSGVS	To The General Manager, Listing Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400 001 Scrip Code: 506197
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------

Dear Sir/Madam,

Subject: Outcome of Board Meeting held on Tuesday, May 11, 2021

We would like to inform you that, the Board Meeting of the Company was held today i.e. Tuesday, May 11, 2021 at the registered office of the Company. In pursuant to Regulation 30 and Regulation 33 read with schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board has considered and approved the following matters:

1. The Audited standalone and consolidated financial results of the Company for the quarter and year ended March 31, 2021 along with the audit report of the auditors. The copy of said financial results and audit reports are enclosed herewith as' Annexure -1';
1. Declaration of unmodified opinion for annual audited standalone and consolidated financial results for the year ended March 31, 2021 in accordance with Regulation 33(3)( d) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI circular no. CIR/CFD/CMD/56/2016 dated May 27, 2016 is enclosed herewith as 'Annexure - 2';
1. Recommended Final dividend of 50% i.e. 0.50 paisa per equity share on face value of Rs. 1/ each for the financial year ended March 31, 2021, subject to approval of the shareholders in the forthcoming Annual General Meeting of the Company;
1. Re-appointment of M/ s. BDO India LLP, Chartered Accountant having LLP registration no. AAB-7880 as Internal Auditor of the Company for the financial year 2021-22. The brief profile

Factory: Regd. Office: 102, Hyde Park, Saki Vihar Road, Andheri (East), Mumbai - 400 072, INDIA. TEL. : (+91) (22) 42160000/ 28505387 • FAX. : (+91) (22) 28563930, Email: [email protected] ·Website: www.blissgvs.com • CIN - L24230MH1984PLC034771 Plot No. 10 & 11 Survey No. 38/1, Dewan Udyog Nagar, Aliyali Village, Tai. & Dist. Palghar - 401 404. Tel. (+91) (02525) 252713 • Fax: (+91) (02525) 255257. • Email : [email protected]

Issue & Allotment of 2,10,500 Equity Shares of face value of Rs. 1 each of the Company under 'Bliss GVS Pharma Limited-Employee Stock Option Plan 2019' ('Bliss GVS ESOP-2019') to the eligible employees under the said Plan, pursuant to exercise of stock options granted thereunder.

Consequent to the aforesaid allotment, Issued, subscribed & paid-up share capital of the Company has increased as under:

From	To
10,31,46,672 equity shares of Re.1 each	10,33,57,172 equity shares of Re.l each
aggregating Rs. 10,31,46,672/-	aggregating Rs. 10,33,57,172 / -

In terms of Regulation lO(c) of the SEBI (Share Based Employee Benefits) Regulations, 2014 (SEBI SBEB Regulations) read with SEBI Circular CIR/CFD/CMD/4/2015 dated September 9, 2015 the details of shares allotted as above are given in' Annexure-4';

1. Re-appointment of Mr. Santosh Laxman Parab (DIN:01622988), as an Non-Executive Independent Director of the Company for a further period of 5 years with effect from 26th May, 2021 to 25th May, 2026, subject to the approval of members in the ensuing Annual General Meeting. The brief profile of Mr. Santosh Laxman Parab is enclosed herewith as 'Annexure-5';
1. Resignation of Mr.SN Kama th from the position of Managing Director as well as membership from all conunittees of board of the Company with inunediate effect i.e. May 11, 2021;
1. Appointment of Mr. Gagan Harsh Sharma (DIN:07939421) as Managing Director of the Company for a period of Three years with effect from 11th May, 2021 to 10th May, 2024, subject to the approval of members in the ensuing Annual General Meeting. The brief profile is enclosed herewith as' Annexure-6'.
1. The Board reconstituted the following conunittees:
a. Audit Committee
b. Corporate Social Responsibility Committee

The Reconstitution is enclosed herewith as' Annexure -7'.

Regd. Office : 102, Hyde Park, Saki Vihar Road, Andheri (East), Mumbai - 400 072, INDIA. TEL.: (+91) (22) 42160000/ 28505387 • FAX.: (+91) (22) 28563930, Email: [email protected] •Website: www.blissgvs.com • CIN - L24230MH1984PLC034771 Factory : Plot No. 1 O & 11 Survey No. 38/1, Dewan Udyog Nagar, Aliyali Village, Tai. & Dist. Palghar - 401 404. Tel. (+91) (02525) 252713 • Fax: (+91) (02525) 255257. • Email : [email protected]

BLISS GVS PHARMA LTD.

The meeting of the Board of Directors conunenced at 12:30 p.m. and concluded at 07:20 p.m. Kindly take the above information on your record and acknowledge.

Thanking you.

Your Faithfully,

Encl: As abov For Bliss GV Pharma Limited

Factory: Regd. Office: 102, Hyde Park, Saki Vihar Road, Andheri (East}, Mumbai - 400 072, INDIA. TEL.: (+91) (22) 42160000/ 28505387 • FAX.: (+91) (22) 28563930, Email: [email protected] •Website: www.blissgvs.com • CIN - L24230MH1984PLC034771 Plot No. 10 & 11 Survey No. 38/1, Dewan Udyog Nagar, Aliyali Village, Tai. & Dist. Palghar - 401 404. Tel. (+91) (02525) 252713 • Fax: (+91) (02525} 255257. • Email :·[email protected]

				c 0 .;; , e ~
			'll -e M " c a			jfN -e
			iE ~ 2 e o i e N			"'0 'Es



		N N a, N COO N ,- .,,. N ,:	0"' N ,: ~ g; 0() .,, .,,-	N N 0()"' tn tn s ~ .,-					r< N \D ui "' 0 .,,. "
	] .;; 8 -e ~ '2 "' :f i a. .5
		"" .,, ~ -				N 0 .-. ~ -	"' .,. ~ 00 ,;	N ~ -	0 .; :;; -
			"' .-. "'	"' .,, ni ""
						0 ni 0() 0()
					"' "' :ti N ,-	N ~ ,-
		N "' .,; ~
>									0 0 " P4 co "" "'"" N~

					"'"' ,: 0() N ,._ ~~i "'
		~ "'
><					N N 0"' ~a	~t-~+-+-~~~~~~~---~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
									.,, 'j, N
		0() ,: :;:
								lo "' 0 ::i g :'.} N

								,-. N "' ~ s "' N "'
		,._ " a -			~ 0 -					s "" 0 -	" a -
							"' "' .,, ci ci	.,. " 0()"' N N	.,, .,, 00 00 O ci

(, in Lakh)

BLISS GVS PHARMA LIMITED

Regd. Office - 102, Hyde Park, Saklnaka Road, Andheri East- Mumbai-400072

Balance Sheet as at March 31, 2021

	Standalone		Consolidated
Particulars	As at March 31 , 2021	As at March 31, 2020	As at March 31, 2021	As at March 31, 2020
	Audited	Audited	Audited	Audited
ASSETS
NON CURRENT ASSETS
(a) Property, Plant and Equipment	17,356.14	17,828.64	22,542.85	23,261.62
(b) Capital work-in-progress	239.49	-	239.49	-
(c) Investment property	68.93	69.09	68.93	69.09
(d) Goodwill	-	-	771.11	771.11
(e) Other intangible assets	53.38	57.08	57.85	64.23
(f) Financial Assets
(i) Investments	1,829.80	1,831.27	1.00	2.46
(ii) Loans	193.90	180.84	210.38	197.33
(Ill) Others	6,200.32	.100.00	6,200,32	100.00
(g) Other non-current assets	955.90	1,178.85	1,066.69	1,282.55
	26,897.86	21,245.77	31,158.62	25,748.39
CURRENT ASSETS
(a) Inventories	8,367.69	6,057.42	9,892.74	7,413.80
(b) Financial Assets
(i) Trade receivables	34,868.09	40,490.52	46,382.03	54,791.18
(ii) Cash and cash equivalents	420.99	1,077.80 7,584.65	1,263.47 13,191.59	1,508.94 8,822.70
(iii) Bank balances other than (ii) above	11,530.92	4,685.81	15.54	17.36
(iv) Loans (v) Others	6,488.30 2,220.87	1,530.10	1,612.00	1,036.67
(c) Current tax assets (Net)	38.92	-	142.71	46.41
(d) Other current assets	3,728.43	2,838.74	4,019.88	3,336.58
	67,664.21	64,265.04	76,519.96	76,973.64
TOTAL ASSETS	94,562.07	85,510.81	1,07,678.58	1,02,722.03
EQUITY AND LIABILITIES
EQUITY
(a) Equity Share Capital	1,031.47	1,031.47	1,031.47	1,031.47
(b) Other Equity	74,533.27	67,262.76	79,793.88	72,529.83
(c) Non Controlling Interest	-	-	1,965.60	1,475.91
LIABILITIES
NON-CURRENT LIABILITIES
Liabilities (a) Financial
(i) Borrowings (ii) Lease Liabilities	3,249.09 182.91	3,554.56 297.42	3,260.39 182.91	3,723.85 297.42
(b) Provisions	249.75	243.94	249.75	243.94
(c) Deferred tax liabilities (Net)	704.91	570.40	820.91	355.47
(d) Other non-current liabilities	-	-	10.09	11.44
	4,386.66	4,666.32	4,524.05	4,632.12
CURRENT LIABILITIES
(a) Financial Liabilities
(i) Borrowings	3,537.76	3,594.02	6,503.77	6,638.52
(ii) Trade payables
(A) Total outstanding dues of micro	535.55	772.91	1,011.89	1,044.13
enterprises and small enterprises (B) Total outstanding dues of other than
micro enterprises and small enterprises	6,141.98	4,821.67	6,410.58	7,947.59
(Iii) Lease Liabilities	114.51	197.23	131.82	218.83
(iv) Other financial liabilities	3,207.31	2,560.82	3,436.16	2,961.61
(b) Other current liabilities	914.31	516.73	1,800.65	2,540.77
(c) Provisions	159.25	6.31	866.08	1,342.91
(d) Current tax liabilities (Net)	-	80.57	202.63	358.34
	14,610.67	12,550.26	20,363.58	23,052.70
TOTAL EQUJJY &-LLJ}_BILITIES	94,562.07	85,510.81	1,07,678.58	1,02,722.03

BLISS GVS PHARMA LTD

Regd. Office - 102, Hyde Park, Sak;n~ka Road, Andheri East- Mumbai-400072 Statement of Cash Flow for the year ended March 31, 2021

(" in lakh) Standalone Consolidated For the year ended For the year ended For the year ended For the year ended Particulars March 31, 2021 March 31, 2020 March 31, 2021 March 31, 2020 Audited Audited Audited Audited A. CASH FLOW FROM OPERATING ACTIVITIES Net Profit before taxation and exceptional items 9,118.67 12,171.25 10,412.70 14,234.60 Less : Exceptional Items - - - 1,338-10 Net Profit before Tax 9,118.67 12,171.25 10,412.70 12,896.50 Adjustment for: Finance costs 419.39 662.38 551.37 747.60 Depreciation and amortisation expense 1,376.22 883.07 1,722.97 1,258.92 Interest Income (1,095.75) (625.89) (957.84) (667.88) Provision for Employee Benefits 73.79 13.86 83.79 13.86 (Profit) /loss on sate/scrap/writtenoff of f;~ed assets (Net) 3.08 {30.13) 3.08 (36.Q4) (Gain)/ Loss on foreign exchange fluctuations (net) 1,776.56 {1,800.83) 1,664.64 (1,231.91) Dividend Income - (12.60) - (0.15) Bad debts written off 154.95 128 02 154.95 12802 Allowance and Provision for Doubtful Debts 240.79 406.39 240.79 415.45 Share Based Payment Expenses 983.76 - 983.76 - Balance Written off/ (back) and other non cash item 181.63 719.11 181.63 719.04 Investment Written off - - - 1,338.10 4,114.42 343.38 4,629.14 2,685.01 Operating profit before working capital changes 13,233.09 12,514.63 15,041.84 15,581.51 Movement in Working capital Trade receivables 3,505.85 (5,158.97) 6,292.56 {7,853.11) Inventories {2,511.43) (1,158.26) (2,680.11) 80.55 Loans and Other Financial Asset {6,160.77) 624.24 {6,257.64) 724.04 Other assets (901.65) 12.52 (695.09) {469.58) Trade Payables 1,184.59 2,279.27 (1,467.62) 1,284.13 Other Financial Liabilities 109.77 73.38 589.39 (692.50) Other Liabilities & Provisions 509.19 321.07 (1,570.11) (105.69) (4,264.45) (3,006.75) {5,788.62) {7,032.16) Cash generated from operations 8,968.64 9,507.88 9,253.22 8,549.35 Less: Income tax (Paid)/ Refunds (2,271.92) {3,186.18) {2,856.28) (3,879.17) Net Cash Flow from Operating Activities 6,696.72 6,321.70 6,396.94 4,670.18 B. CASH FLOW FROM INVESTING ACTIVITIES Payment for property, plant and eqoipment & CWIP {805.91) {6.809.96) {912.42) {5,925.96) Proceeds from sale of property, plant and equipment 42.07 79.31 42.06 85.56 (Increase)/ Decrease in Other Bank Balances (3,946.27) 269.31 {4,368.89) 236.63 Interest received 463.75 773.52 538.1?9 809.67 Dividend Received - 12.60 - 0.15 Loan given to subsidiaries (1,915.69) (338.63) 1.46 4.59 Net Cash Flow from Investing Activities (6,162.05) (6,013.85) {4,699.10) (4,789.36) c. CASH FLOW FROM FINANCING ACTIVITIES Proceeds from Secured borrowings 1,936.41 2,543.47 966.50 2,840.91 Payment of Secured borrowings (1,711.12) (1,258.20) (1,634.18) {1,485.38) Payment of Lease liabilities (219.90) (226.86) {225.20) {247.76) Finance cost paid (617.73) (400.57) (631.97) (482.95) Dividend paid {including Dividend Tax) {554.95) (1,241.02) (554.95) (1,250.00) Cashflow on account of W/off of Investment in stepdown subsidiary - - - (5.28) Net Cash Flow from Financing Activities (1,167.29) {583.18) (2,079.80) (630.46) Net increase in cash and cash equivalents (A+B+C) {632.62) (275.33) {381.96) {749.64) Cash and cash equivalents at the beginning of the year 1,099.72 1,375.05 1,533.95 1,503.65 Effect of exchange on resttitement of foreign currency - - 161.46 774.66 Cash and cash equivalents of Stepdown subsidiary - - - 5.28 Cash and cash equivalents at the end of year• 467.10 1,099.72 1,313.45 1,533.95

* lnclud,ng balance of~ 49 97 Lakh (P.Y.~ 25.02 Lakh) with gratutly bank account and Un,~;,lisf"d e,·change flutudtion.

Notes:

1 The above Cash Flow Statement has been prepared under the 'Indirect Method' as set out in the Indian Accounting Standard 7 "Statement of Cash Flow"

Notes:

¹The above results which are published in accordance with Regulation 33 of the SEBI (Listing Obligation & Disclosure Requirements), 2015 have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on May 11, 2021. The financial results are in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules in this regard.
2 The disclosure is an extract of audited financials statement as at March 31, 2021 prepared in compliance with the Indian Accounting Standard (Ind AS) which have been audited by statutory Auditor. The statutory auditors, Kalyaniwalla & Mistry LLP have issued report with unmodified opinion on the standalone and consolidated financial results.
3 As the Company's business activity falls within a single operating segment viz "Pharmaceutical and Healthcare", no segment information is disclosed.
4 The Indian Parliament has approved the Code on Social Security, 2020 which would impact the contributions by the company towards Provident Fund and Gratuity. The Ministry of Labour and Employment has released draft rules for the Code on Social Security, 2020 on November 13, 2020. However, the date on which the code will come into effect has not been notified. The Company and its Indian subsidiaries will assess the impact and will record any related impact in the period once the code becomes effective.
⁵In March 2020, the World Health Organisation declared COVID-19 to be a pandemic. The Group has adopted measures to curb the spread of infection in order to protect the health of its employees and ensure business continuity with minimal disruption. The Group has considered internal and external information while finalizing various estimates in relation to its financial results captions upto the date of approval of the financial results by the Board of Directors. The actual impact of the global health pandemic may be different from that which has been estimated, as the COVID -19 situation evolves in India and globally. The Group will continue to closely monitor any material changes to future economic conditions.
6 Employee Benefit Expenses includes Share Based Payment on account of ESOP Scheme, 2019 of~ 983.76 Lakhs as per Ind AS 102 for year ended March 31, 2021. Under this scheme the outstanding number of options are 23,31,000 as at March 31, 2021.
7 Exceptional items for financial year ended March 31, 2020 includes ~ 1,338 Lakhs on account of write off of investments in a step down subsidiary namely Eco Rich Cosmetics India Pvt. Ltd. due to loss of control w.e.f. January 1, 2020.
8 For Financial Year 2021, the board has recommended final dividend~ 0.50/- per share. The payment is subject to approval of the shareholders in the ensuring Annual General Meeting of the company.
9 The figures for the quarter ended March 31, 2021 and March 31, 2020 are the balancing figures between audited figures in respect of the full financial year ended March 31 and the year to date published result for the nine months ended December 31, 2020 and December 31, 2019.
10 Previous year figures have been regrouped/reclassified wherever necessary.

Place: Mumbai Date: May 11, 2021

Din No: 00731501

CHARTERED ACCOUNTANTS

Independent Auditor's Report on Quarterly and Annual Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

TO THE BOARD OF DIRECTORS OF BLISS GVS PHARMA LIMITED

Opinion

We have audited the accompanying consolidated financial results of Bliss GVS Pharma Ltd (''the Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group")for the quarter ended March 31, 2021 and for the period from April O 1, 2020 to March 3 J, 2021, attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (''SEBI") (Listing Obligations and Disclosure Requirements) Regulations. 2015. as amended ('"Listing Regulations").

Attention is drawn to the fact that the figures for the quarters ended March 31, as reported in these results are the balancing figures between audited figures in respect of the year ended on March 31, and the published year to date figures up to the end of the third quarter of the relevant financial years. Also, the figures up to the end of the third quarter had only been reviewed and were not subjected to audit.

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the reports of the other auditors on separate financial statements/ financial information of subsidiaries, the Statement:

includes the results of the following entities:

Incorporated in India:

I. K.remoint Pharma Private Ltd. India. 1.1. EIPII Exports Private Ltd, India.

Incorporated outside India:

1. Bliss GVS International Pte. Ltd, Singapore 2.1. Greenlife Bliss Healthcare Ltd, Nigeria
1. Bliss GVS Clinic Health Care Pte. Ltd, Singapore.
1. Asterisk Lifesciences Limited, United Kingdom. 4.1. Asterisk Lifesciences (GH) Limited, Ghana.
ii. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
iii.give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards and other accounting principles generally accepted in India. of the consolidated net profit and consolidated other comprehensive income and other financial information of the Group for the quarter ended March 31, 2021 as well as the year to date results for the period from April OJ, 2020 to March 31, 2021.

Page I of 4

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ( .. SAs'') specified under section 143(10) of the Companies Act. 2013 ('·the Act"). Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Results section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (vthe ICAI") together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us and other auditors in terms of their reports referred to in "Other Matter" paragraph below, is sufficient and appropriate to provide a basis for our opinion.

Management's Responsibilities for the Consolidated Financial Results

These quarterly and annual consolidated financial results have been prepared on the basis of the consolidated financial statements. The Holding Company's Board of Directors are responsible for the preparation of these consolidated financial results that give a true and fair view of the net profit and other comprehensive income and other financial information of the Group in accordance with the recognition and measurement principles laid down in Indian Accounting Standards ( .. Ind AS") prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated financial results by the Directors of the Holding Company, as aforesaid.

In preparing the consolidated financial results, the respective Board of Directors of the companies included in the Group are responsible for as sessing the Group ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors of the companies included in the Group either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are also responsible for overseeing the financial reporting process of the Group.

Auditor's Responsibilities for the Audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the consolidated financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered

material if. individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial results.

As part of an audit in accordance with SAs. we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

Identify and assess the risks of material misstatement of the consolidated financial results, whether due to fraud or error. design and perform audit procedures responsive to tho e risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of consolidated financial statements on whether the entity has adequate internal financial controls with reference to consolidated financial statements in place and the operating effectiveness of such controls.
Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
Evaluate the overall presentation, structure and content of the consolidated financial results, including the disclosures, and whether the consolidated financial results represent the underlying transactions and events in a manner that achieves fair presentation.
Obtain sufficient appropriate audit evidence regarding the financial results/financial information of the entities within the Group to express an opinion on the consolidated Financial Results. We are responsible for the direction. supervision and performance of the audit of financial information of such entities included in the consolidated financial results of which we are the independent auditors. For the other entities included in the consolidated Financial Results, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion. Our responsibilities in this regard are further described in "Other Matters" paragraph in this audit report.

We communicate with those charged with governance of the Holding Company and such other entities included in the consolidated financial results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.

Other Matters

The Consolidated Financial Results include the audited financial results of seven subsidiaries I Step Down Subsidiaries included in the consolidated financial results, whose financials statement I financial information reflect the Group's share for the quarter and year ended March 31, 2021 for the under mentioned items:

			(Rs. In Lakhs)
Sr No	Particulars	Quarter ended March 31, 2021	Year ended March 31, 2021
1	Total Assets	13,116.51	13,116.51
2	Total Revenue	2,682.10	169.23 11,
, .)	Profit after Tax	(100.89)	647.08
4	Total Comprehensive Income	200.37	543.39
5	Net Cash outflows I (inflows)	NA	(250.66)

The financial statement of these subsidiaries has been audited by their respective independent auditors. The independent auditors' reports on financial statements I Financial Results I financial information of these entities have been furnished to us and our opinion on the consolidated Financial Results, in so far as it relates to the amounts and disclosures included in respect of these entities, is based solely on the report of such auditors and the procedures performed by us are as stated in paragraph above.

Our opinion on the consolidated Financial Results is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors.

For KAL Y ANIW ALLA & MISTRY LLP CHARTERED ACCOUNT ANTS Firm Registration No. 104607W I W 100166

Sai Venkata Ramana Damarla ((i{~uMs~~)~t Partner ~tJ:~~~'f' Membership. No. 107017 ~,,. UDIN: ZI (O;:J-o/=f/tftMfY!r-?-..16'

Place: Mumbai Dated: May 11, 2021.